NSB NeuroScientific Biopharmaceuticals Limited
Healthcare · Biotechnology
· website
$0.06
52wk 0.06 – 0.18
Overall
42.8
Value
70.0
Growth
50.0
Health
69.2
Quality
0.0
Momentum
4.6
Dividend
—
Price
About NeuroScientific Biopharmaceuticals Limited
NeuroScientific Biopharmaceuticals Limited engages in the research and development of biomedical products targeting neurodegenerative conditions and immune-mediated inflammatory diseases. Its lead product is the EmtinB drug for the treatment of optic nerve diseases, such as glaucoma. The company also develops StemSmart platform technology to treat inflammatory immune disorders. NeuroScientific Biopharmaceuticals Limited was incorporated in 2002 and is based in Perth, Australia.
Price analytics
Returns
| 1 day | -6.5% |
| 1 week | -6.5% |
| 1 month | -4.9% |
| 3 months | -18.3% |
| 6 months | -41.4% |
| 1 year | -62.6% |
| 3 years | -3.3% |
Risk
| Volatility (1y ann.) | 110.8% |
| Beta vs ASX 200 | 0.77 |
| Sharpe (1y) | -0.40 |
| VaR 95% (1-day) | -9.3% |
| Max drawdown (1y) | -66.1% |
| Off 1-year high | -64.8% |
Technicals
| RSI(14) | 44 |
| vs 50DMA | -6.1% |
| vs 200DMA | -35.5% |
| Trend | Death cross |
Fundamental trends
Financial statements
Loading…
Scoring breakdown
(2 Oct 2026)
Value
70.0
Trailing P/E
—
Forward P/E
—
PEG ratio
—
EV / EBITDA
100
Price / Book
90
Price / Sales
0
Growth
50.0
Revenue growth (1y)
100
Revenue CAGR (3y)
—
EPS growth (1y)
0
EPS CAGR (3y)
—
Financial Health
69.2
Net debt / EBITDA
—
Interest coverage (EBIT/interest)
0
Current ratio
100
Debt / Equity
100
Quality (Profitability & Cash Flow)
0.0
Return on equity
0
Return on assets
0
Operating margin
0
Net margin
0
Cash conversion (OCF / net income)
—
Dividend / Income
—
No meaningful dividend — pillar excluded from the overall score.
Momentum
4.6
6-month return vs ASX 200
0
Price vs 200-day average
0
Price vs 50-day average
20
Position in 52-week range
2
Hover a row's info icon for the exact rule. Bounds and weights are configurable in the Django admin (Scoring configuration).
Score history
Key metrics
Market cap
$22.60M
P/E (trailing)
—
P/E (forward)
—
EPS (trailing)
-0.01
Dividend yield
—
Payout ratio
0.0%
Beta
1.12
EV / EBITDA
-5.44
Price / Book
1.53
ROE
-29.7%
Operating margin
-3,407.5%
Net margin
0.0%
Total cash
$4.63M
Total debt
$87,039
Current ratio
14.27
Debt / Equity
0.01
Free cash flow
$-1.04M
Avg volume
165,314
Latest annual results
(FY ending 30 Jun 2026)
- Revenue—
- Gross profit—
- Operating income-$5.11M
- Net income-$4.69M
- Diluted EPS—
- Free cash flow-$2.78M
- Net debt-$2.54M